City of Hope^®, one of the largest and most advanced cancer research and treatment organisations in the U.S. with its National Medical Centre named top 5 in the nation for cancer by U.S. News & World Report, has opened a phase 1 trial seeking to one day transform rectal cancer from a mostly radiation-resistant disease to one that can be cured using radiation and chemotherapy.

“Many cancers are cured through radiation therapy alone or radiation in combination with chemotherapy, including — but not limited to — prostate, head and neck, lung, cervical and anal cancers. For patients who are eligible for a watch-and-wait approach, improving the efficacy of radiation and avoiding the need for surgery may improve quality of life, particularly if patients receiving surgery will need a permanent colostomy and require stool to be collected in an external bag,” said Terence Williams, M.D., Ph.D., chair of the Department of Radiation Oncology at City of Hope and principal investigator of the clinical trial (NCT06834126).

Papaverine is an investigational drug that was found in both preclinical and ongoing clinical trials to sensitise tumour cells to radiation therapy by blocking oxygen consumption in tumour cells.

The researchers will test to see if papaverine can be used in a different way to turn off oxygen consumption in the tumour cell and raise oxygen content.

Since radiation works better when oxygen is present, the physician scientists believe this technique will allow for maximal tumour destruction and prevent or prolong the need for rectal cancer surgery.

City of Hope’s DINOMITE trial has a primary goal of determining the side effect profile and most effective dose of papaverine when given with radiation therapy to patients with rectal cancer that has spread to nearby tissue or lymph nodes (locally advanced) but that has not spread beyond the pelvis.

Surgery would be reserved for patients whose tumours recur in the pelvis after radiation and chemotherapy.

The ultimate goal in this trial will be to improve radiation therapy in a way that sensitises tumours, but not normal organs and tissues, to radiation therapy and prevent patients with localised rectal cancer from needing surgery.

City of Hope experts are leveraging a discovery made in the laboratory, building upon recent work in Dr. Williams’ lab and prior work at a colleague’s lab.

City of Hope is a leading institution known for its "bench to bedside" approach to translational medicine, rapidly moving research from the lab to clinical trials and patient care.

March is Colorectal Cancer Awareness Month, and rectal cancer constitutes about a third of colorectal cancer.

Innovations in radiation oncology to make radiation work more effectively, such as the approach to be tested in this trial, could prevent the need for patients to undergo a life-changing surgery.

Source: City of Hope